Disclosures for "Pharmacological inhibition of FGFR by infigratinib reduces lipids associated with neurodegeneration in MOG35-55-induced EAE")
-
Dr. Berghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Idec. Dr. Berghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Berghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Berghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Berghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MerckSerono. Dr. Berghoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Berghoff has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Berghoff has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. The institution of Dr. Berghoff has received research support from Novartis.
-
Natascha Wallendszus has nothing to disclose.
-
Mr. Rajendran has nothing to disclose.
-
Dr. Liebisch has nothing to disclose.
-
Srikanth Karnati has nothing to disclose.
-
Mr. Rajendran has nothing to disclose.